Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review
{{output}}
The combination of DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) has been extensively studied to improve therapeutic outcomes. While both groups of agents show promise individually, DDAs are limited by tumor resistance, and DDRis are li... ...
